-transparent.png){kind=logo}
Drosophila cells were treated in vitro with N-phosphonacetyl-L-aspartate (PALA) which is a specific inhibitor of aspartate transcarbamylase, the second enzyme of the pyrimidine biosynthetic pathway. By stepwise selection using increasing amounts of this inhibitor, PALA-resistant (PALAr) stable clones have been isolated. Enzymatic activities of aspartate transcarbamylase, carbamyl phosphate synthetase and dihydro-orotase, borne by the same multifunctional protein, CAD, are increased 6-12-fold in these resistant clones compared with parental cells. The aspartate transcarbamylase in PALAr cells is shown by physical, kinetic and immunological criteria to be normal. The data from immunotitration and immunoblotting experiments indicate that the increased enzyme activities result from the overproduction of CAD.
M Laval, and
Y Azou, and
D Giorgi, and
R Rosset
September 1979,
The Journal of biological chemistry,
M Laval, and
Y Azou, and
D Giorgi, and
R Rosset
October 1982,
Biochemical pharmacology,
M Laval, and
Y Azou, and
D Giorgi, and
R Rosset
August 1979,
Cancer research,
M Laval, and
Y Azou, and
D Giorgi, and
R Rosset
December 1976,
Cell,
M Laval, and
Y Azou, and
D Giorgi, and
R Rosset
November 1978,
Developmental biology,
M Laval, and
Y Azou, and
D Giorgi, and
R Rosset
June 1981,
Lancet (London, England),
M Laval, and
Y Azou, and
D Giorgi, and
R Rosset
January 1980,
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
M Laval, and
Y Azou, and
D Giorgi, and
R Rosset
November 1984,
Biochemical pharmacology,
M Laval, and
Y Azou, and
D Giorgi, and
R Rosset
April 1986,
Biochemical and biophysical research communications,
M Laval, and
Y Azou, and
D Giorgi, and
R Rosset
October 1982,
Biochemical pharmacology,
